HOOK vs. GRTS, NTGN, ME, RVNC, CRMD, XOMA, MRSN, VNDA, XERS, and EPIX
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Gritstone bio (GRTS), Neon Therapeutics (NTGN), 23andMe (ME), Revance Therapeutics (RVNC), CorMedix (CRMD), XOMA (XOMA), Mersana Therapeutics (MRSN), Vanda Pharmaceuticals (VNDA), Xeris Biopharma (XERS), and ESSA Pharma (EPIX). These companies are all part of the "medical" sector.
Hookipa Pharma (NASDAQ:HOOK) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
In the previous week, Gritstone bio had 2 more articles in the media than Hookipa Pharma. MarketBeat recorded 7 mentions for Gritstone bio and 5 mentions for Hookipa Pharma. Gritstone bio's average media sentiment score of 0.76 beat Hookipa Pharma's score of 0.70 indicating that Gritstone bio is being referred to more favorably in the news media.
Hookipa Pharma has a net margin of -88.73% compared to Gritstone bio's net margin of -926.13%. Hookipa Pharma's return on equity of -33.33% beat Gritstone bio's return on equity.
Hookipa Pharma has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Hookipa Pharma presently has a consensus target price of $4.67, indicating a potential upside of 520.82%. Gritstone bio has a consensus target price of $4.75, indicating a potential upside of 536.39%. Given Gritstone bio's higher probable upside, analysts plainly believe Gritstone bio is more favorable than Hookipa Pharma.
Gritstone bio received 55 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 69.46% of users gave Gritstone bio an outperform vote while only 69.35% of users gave Hookipa Pharma an outperform vote.
63.9% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 48.5% of Gritstone bio shares are owned by institutional investors. 3.3% of Hookipa Pharma shares are owned by insiders. Comparatively, 4.6% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Hookipa Pharma has higher revenue and earnings than Gritstone bio. Hookipa Pharma is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Summary
Gritstone bio beats Hookipa Pharma on 9 of the 17 factors compared between the two stocks.
Get Hookipa Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
